After excluding the experimental drugs, the drugs that target MM gene molecules with an off-target MOA, the drugs that are currently used in MM treatment and the drugs that have already been evaluated for the treatment of MM in previous clinical trials, we resulted in 11 drugs that target 4 MM key genes (EDNRB, HGF, CCL3 and ADM). This evidence concerns the gene ADM and Miyoshi myopathy.